Short Interest in Delcath Systems, Inc. (NASDAQ:DCTH) Drops By 23.0%

Delcath Systems, Inc. (NASDAQ:DCTH - Get Free Report) was the recipient of a significant drop in short interest during the month of January. As of January 15th, there was short interest totalling 1,040,000 shares, a drop of 23.0% from the December 31st total of 1,350,000 shares. Based on an average daily volume of 386,900 shares, the short-interest ratio is presently 2.7 days.

Analyst Ratings Changes

DCTH has been the topic of a number of recent research reports. Craig Hallum upped their target price on Delcath Systems from $18.00 to $21.00 and gave the stock a "buy" rating in a research note on Friday, January 17th. StockNews.com upgraded Delcath Systems from a "sell" rating to a "hold" rating in a research report on Friday, October 25th. HC Wainwright reaffirmed a "buy" rating and set a $22.00 target price on shares of Delcath Systems in a report on Tuesday, January 14th. Stephens reiterated a "buy" rating on shares of Delcath Systems in a research note on Friday, October 18th. Finally, Canaccord Genuity Group restated a "buy" rating and set a $21.00 price target on shares of Delcath Systems in a research report on Friday, October 18th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $22.25.

Delcath Systems Stock Performance

Delcath Systems stock traded up $0.46 during trading on Thursday, reaching $16.11. The company had a trading volume of 100,048 shares, compared to its average volume of 496,615. The firm has a market capitalization of $515.04 million, a PE ratio of -11.93 and a beta of 0.87. The firm's 50-day simple moving average is $12.42 and its 200 day simple moving average is $10.35. Delcath Systems has a 1-year low of $3.70 and a 1-year high of $16.44.

Institutional Trading of Delcath Systems

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Marshall Wace LLP lifted its stake in Delcath Systems by 7.0% in the 2nd quarter. Marshall Wace LLP now owns 92,731 shares of the company's stock valued at $776,000 after buying an additional 6,066 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Delcath Systems by 3.0% in the third quarter. Geode Capital Management LLC now owns 251,895 shares of the company's stock worth $2,275,000 after acquiring an additional 7,298 shares during the last quarter. State Street Corp increased its position in shares of Delcath Systems by 12.4% during the third quarter. State Street Corp now owns 85,457 shares of the company's stock worth $772,000 after purchasing an additional 9,400 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in Delcath Systems in the 3rd quarter valued at $102,000. Finally, Barclays PLC purchased a new position in Delcath Systems in the 3rd quarter valued at $104,000. Hedge funds and other institutional investors own 61.12% of the company's stock.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.